SCYNEXIS, Inc.
P.O. Box 12878
Research Triangle Park
North Carolina
27709
United States
Tel: 919-544-8600
Fax: 919-544-8697
Website: http://www.scynexis.com/
Email: terry.marquardt@scynexis.com
330 articles about SCYNEXIS, Inc.
-
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
11/12/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, 2019, and provided an update on recent clinical developments.
-
Clinical Catch-Up: November 4-8
11/11/2019
It was a busy week for clinical trial updates for the first week of November. Here’s a look. -
SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
11/7/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).
-
SCYNEXIS Announces Oral Presentation of Data from Ibrexafungerp Phase 2b DOVE Study at the 3rd ISIDOG Congress
10/31/2019
In the DOVE study, fluconazole was the predominant rescue therapy when patients in the fluconazole arm failed therapy, underscoring the need for new VVC therapeutic options
-
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
10/24/2019
Use of oral ibrexafungerp expanded to patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections
-
SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
10/10/2019
SCYNEXIS, Inc. has received notification from the State of New Jersey of its available unused net operating losses (NOLs) and R&D tax credits that can be sold under the New Jersey Economic Development Authority's (NJEDA) Technology Business Tax Certificate Transfer (NOL) program.
-
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
10/2/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that data, which further demonstrates the potential of ibrexafungerp as a treatment for invasive fungal infections, will be presented at IDWeek 2019, occurring October 2-6, 2019 in Washington DC, and TIMM-9, occurring October 11-14, 2019 in Nice, France
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
9/18/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced completion of the last-patient/last-visit in its Phase 3 VANISH 303 study, and that it expects to release top-line data earlier than previously reported. Ibrexafungerp (formerly SCY-078) is the first representative of a novel family of antifungal compounds referred to as triterpenoids
-
SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences
9/4/2019
SCYNEXIS, Inc. announced that the Company will present in the following investor conferences
-
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
8/7/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended June 30, 2019,
-
SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
7/31/2019
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 5:00 p.m. ET.
-
Clinical Catch-up for July 22-26
7/29/2019
A number of companies reported clinical trial data last week. Here’s a look. -
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
7/24/2019
CANDLE study expected to begin enrolling patients with recurrent VVC, a condition with no FDA-approved therapies, this quarter
-
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
6/25/2019
SCYNEXIS, Inc. announced the availability of nine presentations (here) from the American Society for Microbiology (ASM) Microbe 2019, which occurred June 20-24, 2019, in San Francisco.
-
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
6/14/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Nkechi Azie, MD, MBA, FIDSA, as Vice President of Clinical Development, effective June 10, 2019.
-
SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
6/5/2019
New in vivo studies support potential use of ibrexafungerp in skin and invasive infections caused by multidrug-resistant pathogen, Candida auris
-
SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
5/30/2019
SCYNEXIS, Inc. announced that the company has completed the nonclinical toxicology evaluations that are required by regulatory authorities, including the U.S. Food and Drug Administration (FDA), to support long-term administration in human clinical trials.
-
SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update
5/8/2019
Continued advancement of VVC program, including completed favorable embryo-fetal safety profile, further supports a potential first NDA submission of oral ibrexafungerp in the second half of 2020
-
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
5/6/2019
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential of ibrexafungerp as an agent to address VVC.